Several new molecules have been explored as potential HDAC inhibitors that can target multiple classes of HDACs and were shown to induce a range of antitumor activities, including cell cycle arrest, cell death, tumor differentiation, and increased tumor immunogenicity [73]. Here, HDAC9 is linked to neoplasm.